



**I MINA' TRENTA I UNO NA LIHESLATURAN GUAHAN**  
2011 (First) Regular Session

2011 MAY 27 PM 12:13

Bill No. 216-31(COR)

Introduced by:

B.J.F. Cruz   
A.B. Palacios, Sr. 

**AN ACT TO AMEND (C), (D), (E), AND TO ADD A NEW ITEM (F) TO APPENDIX A, TO AMEND (A)(1), (B), AND (C) OF APPENDIX B, TO AMEND (B), (D), (E), AND ADD A NEW (F) TO APPENDIX C, TO AMEND (B) OF APPENDIX D, TO AMEND (D) OF APPENDIX D, TO AMEND (D) OF APPENDIX E OF CHAPTER 67 OF TITLE 9, TO ADD A NEW §3106.1 TO ARTICLE 1 OF CHAPTER 3 OF TITLE 10 OF THE GUAM CODE ANNOTATED RELATIVE TO UPDATING THE GUAM UNIFORM CONTROLLED SUBSTANCE ACT BASED ON THE U.S. DRUG ENFORCEMENT ADMINISTRATION SCHEDULE LISTING.**

1        **BE IT ENACTED BY THE PEOPLE OF GUAM:**

2        **Section 1.** Item (C) of Appendix A of Chapter 67 of Title 9 of the Guam  
3 Code Annotated is hereby *amended* to read as follows:

4        “(C) Material, compound, mixture or preparation containing any quantity of  
5 the following hallucinogenic substances, including any salts, isomers, and  
6 salts of isomers of them that are theoretically possible within the specific  
7 chemical designation:

8                (1) Alpha-ethyltryptamine (other names: etryptamine; Monase; alpha-  
9 ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; alpha-ET;  
10 and AET);

11                (2) 4-bromo-2,5-dimethoxy-amphetamine (other names: 4-bromo-

1 2,5-dimethoxy-alpha-methylphenethylamine; 4-bromo-2,5-DMA);  
2 (3) 4-bromo-2,5-dimethoxyphenethylamine (other names: 2-(4-bromo-  
3 2,5-dimethoxyphenyl)-i-aminoethane; alpha-desmethyl DOB; 2C-B,  
4 Nexus);  
5 (4) 2,5-dimethoxyamphetamine (other names: 2,5-dimethoxyalpha-  
6 methylphenethylamine; 2,5-DMA);  
7 (5) 2,5-dimethoxy-4-ethylamphetamine; Some trade or other names:  
8 DOET  
9 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (other name: 2C-  
10 T-7)  
11 ~~(6)~~ (7) 4-methoxyamphetamine (other names: 4-methoxy-  
12 alphanethylphenethylamine; paramethoxyamphetamine, PMA);  
13 ~~(7)~~ (8) 5-methoxy-3,4-methylenedioxy-amphetamine;  
14 ~~(8)~~ (9) 4-methyl-2,5-dimethoxy-amphetamine (other names: 4-methyl-  
15 2,5-dimethoxy-alpha-methylphenethylamine; DOM; and STP);  
16 ~~(9)~~ (10) 3,4-methylenedioxy amphetamine;  
17 ~~(10)~~ (11) 3,4-methylenedioxymethamphetamine (MDMA);  
18 ~~(11)~~ (12) 3,4-methylenedioxy-N-ethylamphetamine (other names:  
19 Nethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl  
20 MDA, MDE, MDEA);  
21 ~~(12)~~ (13) N-hydroxy-3,4-methylenedioxyamphetamine (other names:  
22 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and  
23 Nhydroxy MDA);  
24 ~~(13)~~ (14) 3, 4, 5-trimethoxy amphetamine;  
25 (15) Alpha-methyltryptamine (others name: AMT)  
26 ~~(14)~~ (16) bufotenine (other names: 3-(beta-Dimethylaminoethyl)-5-

1 hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,  
2 Ndimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine);  
3 ~~(15)~~ (17) diethyltryptamine (other names: N,N-Diethyltryptamine;  
4 DET);  
5 ~~(16)~~ (18) dimethyltryptamine (other names: DMT);  
6 (19) 5-mthoxy-N,N-diisopropyltryptamine (other name: 5-MeO-  
7 DIPT)  
8 ~~(17)~~ (20) ibogaine (other names: (7-Ethyl-6,6Beta, 7, 8, 9, 10, 12, 13-  
9 octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino  
10 [5,4-b] indole; tabernanthe iboga);  
11 ~~(18)~~ (21) lysergic acid diethylamide;  
12 ~~(19)~~ (22) marihuana;  
13 ~~(20)~~ (23) mescaline;  
14 ~~(21)~~ (24) parahexyl (other names: 3-Hexyl-1-hydroxy-7, 8, 9, 10-  
15 tetrahydro-6, 6, 9-trimethyl-6H-dibenzo [b, d] pyran; Synhexyl);  
16 ~~(22)~~ (25) peyote (all parts of the plant presently classified botanically  
17 as Lophophora williamsii Lemaire, whether growing or not, its seeds,  
18 any extract from any part of the plant, and every compound  
19 manufacture, salts, derivative, mixture, or preparation of such plant,  
20 its seeds or extracts);  
21 ~~(23)~~ (26) N-ethyl-3-piperidyl benzilate;  
22 ~~(24)~~ (27) N-methyl-3-piperidyl benzilate;  
23 ~~(25)~~ (28) psilocybin;  
24 ~~(26)~~ (29) psilocyn;  
25 ~~(27)~~ (30) tetrahydrocannabinols;

1           ~~(28)~~ (31) ethylamine analog of phencyclidine (other names: N-ethyl-  
2           1-phenylcyclohexylamine; (1-phenylcyclohexyl) ethylamine, N-  
3           (lphenylcyclohexyl) ethylamine; cyclohexamine, PCE);

4           ~~(29)~~ (32) pyrrolidine analog of phencyclidine (other names: 1-  
5           (lphenylcyclohexyl)- pyrrolidine, PCPy; PHP);

6           (33) Tetrahydrocannabinols (Meaning tetrahydrocannabinols naturally  
7           contained in the plant of the genus Cannabis (cannabis plant), as well  
8           as synthetic equivalents of the substances contained in the cannabis  
9           plant, or in the resinous extractives of such plant, and/or synthetic  
10           substances, derivatives, and their isomers with similar chemical  
11           structure and pharmacological activity to those substances contained  
12           in the plant, such as the following:

13                   -1 cis or trans tetrahydrocannabinol, and their optical isomers

14                   -6 cis or trans tetrahydrocannabinol, and their optical isomers

15                   -3, 4 cis or trans tetrahydrocannabinol, and its optical isomers

16           (Since nomenclature of these substances is not internationally  
17           standardized, compounds of these structures, regardless of numeric  
18           designation of atomic positions covered.)

19           ~~(30)~~ (34) thiophene analog of phencyclidine (other names: 1-[1-(2-  
20           thienyl)-cyclohexyl]-piperidine, 2-thienyl analog of phencyclidine,  
21           TPCP; TCP); and

22           ~~(31)~~ (35) TCPy (other name: 1-[1-(2-thienyl)cyclohexyl] pyrrolidine.”

23           **Section 2.** Item (D) of Appendix A of Chapter 67 of Title 9 of the Guam  
24           Code Annotated is hereby *amended* to read as follows:

25           “(D) Material, compound, mixture or preparation containing any quantity of  
26           the following substances having a depressant effect on the central nervous

1 system, including any salts, isomers and salts of isomers of them that are  
2 theoretically possible within the specific chemical designation:

- 3 (1) gamma-hydroxybutyric acid (some other names include GBH;  
4 gamma-hydroxybutyrate; 4-hydroxybutyrate acid; sodium oxybate;  
5 sodium oxybutyrate)  
6 ~~(1)~~ (2) mecloqualone; and  
7 ~~(2)~~ (3) methaqualone.”

8 **Section 3.** Item (E) of Appendix A of Chapter 67 of Title 9 of the Guam  
9 Code Annotated is hereby *amended* to read as follows:

10 “(E) Material, compound, mixture or preparation containing any quantity of  
11 the following substances having a stimulant effect on the central nervous  
12 system, including their salts, isomers and salts of isomers:

- 13 (1) Aminorex (other names: aminoxaphen; 2-amino-5-phenyl-2-  
14 oxazoline; or 4,5-dihydro-5-phenly-2-oxazolamine);  
15 (2) N-Benzylpiperazine (some other names: BZP, 1-benzylpiperazine)  
16 ~~(2)~~ (3) Cathinone (other names: 2-amino-1-phenyl-1-propanone,  
17 alpha-aminopropiophenone, 2-aminopropiophenone, and  
18 norephedrone);  
19 ~~(3)~~ (4) Fenethylamine;  
20 ~~(4)~~ (5) Methcathinone (other names: 2-(methylamino)-propiofenone;  
21 alpha-(methylamino)propiofenone; 2-(methylamino)-1-  
22 phenylpropan-1-one; alpha-Nmethylaminopropiofenone;  
23 monomethylpropion; ephedrone; Nmethylcathinone; methylcathinone;  
24 AL-464; AL-422; AL-463 and UR1432), its salts, optical isomers and  
25 salts of optical isomers);  
26 ~~(5)~~ (6) (+/-)cis-4-methylaminorex (other name: (+/-)cis-4,5- dihydro-  
27 4-methyl-5-phenyl-2-oxazolamine);

1           ~~(6)~~ (7) N-ethylamphetamine; and  
2           ~~(7)~~ (8) N,N-dimethylamphetamine (other name: N,N-  
3           alphatrimethylphenethylamine).  
4           (9) (other name: N,N-alphatrimethylphenethylamine; N,N-alpha-  
5           trimethylbenzeneethamine).”

6           **Section 4.** A new Item (F) is hereby added to Appendix A of Chapter 67 of  
7 Title 9 of the Guam Code Annotated, to read as follows:

8           “(F) Any material, compound, mixture or preparation which contains any  
9           quantity of the following substances:

- 10           (1) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide  
11           (benzylyfentanyl), its optical isomers, salts and salts of isomers; and  
12           (2) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide  
13           (thenylfentany), its optical isomers, salts and salts of isomers.”

14           **Section 5.** Item (A) (1) of Appendix B of Chapter 67 of Title 9 of the Guam  
15 Code Annotated is hereby *amended* to read as follows:

16           “(A) Any of the following substances, however manufactured:

17           (1) Opium and opium derivative, and any salt, compound derivative,  
18           or preparation of opium or opium derivative, excluding apomorphine,  
19           dextrorphan, nailbuphine, butorphanol, nalmeffene, naloxone, and  
20           naltrexone, but including:

- 21           (A) raw opium;  
22           (B) opium extracts;  
23           (C) opium fluid;  
24           (D) powdered opium  
25           (E) granulated opium;  
26           (F) tincture of opium;  
27           (G) codeine;

- 1 (H) ethylmorphine;
- 2 (I) etorphine hydrochloride;
- 3 (J) hydrocodone;
- 4 (K) hydromorphone;
- 5 (L) metopon;
- 6 (M) morphine;
- 7 (N) oxycodone
- 8 (O) oxymorphone;
- 9 (P) thebaine;
- 10 (Q) dihydroetorphine;
- 11 (R) oripavine.”

12 **Section 6.** Item (B) of Appendix B of Chapter 67 of Title 9 of the Guam  
13 Code Annotated is hereby *amended* to read as follows:

14 “(B) Any of, the following synthetic opiates, including any isomers, esters,  
15 ethers, salts, and salts of isomers, esters, and ethers of them that are  
16 theoretically possible within the specific chemical designation:

- 17 (1) alfentanil;
- 18 (2) alphaprodine;
- 19 (3) anileridine;
- 20 (4) bezitramide;
- 21 (5) carfentanil;
- 22 (6) bulk dextropropoxyphene (non-dosage forms);
- 23 (7) dihydrocodeine;
- 24 (8) diphenoxylate;
- 25 (9) fentanyl;
- 26 (10) isomethadone;
- 27 (11) levomethorphan;

- 1 (12) levorphanol;  
2 (13) metazocine;  
3 (14) methadone;  
4 (15) methadone-intermediate, 4-cyano-2-dimethylamino-4, 4-  
5 diphenyl butane;  
6 (16) moramide-intermediate, 2-methyl-3-morpholino-1,  
7 Idiphenylpropane-  
8 carboxylic acid;  
9 (17) pethidine (meperidine);  
10 (18) pethidine-intermediate-A,4-cyano-1-methyl-4-  
11 phenylpiperidine;  
12 (19) pethidine-intermediate-B, ethyl-4-phenylpiperidine-4-  
13 carboxylate;  
14 (20) pethidine-intermediate-C, 1-methyl-4-phenylpiperidine-4-  
15 carboxylic acid;  
16 (21) phenazocine;  
17 (22) piminodine;  
18 (23) racemethorphan;  
19 (24) racemorphan;  
20 (25) remifentanil  
21 ~~(25)~~ (26) sufentanil; and  
22 ~~(26)~~ (27) levo-alphaacetylmethadol (other names: levo-  
23 alphaacetylmethadol, levomethadyl acetate, LAAM).  
24 (28) tapentadol.”

25 **Section 7.** Item (C) of Appendix B of Chapter 67 of Title 9 of the Guam  
26 Code Annotated is hereby *amended* to read as follows:



1 “(C) Material, compound, mixture, or preparation containing any quantity of  
2 the following substances, their salts, isomers, or salts of isomers, having a  
3 stimulant effect on the central nervous system:

- 4 (1) amphetamine;
- 5 (2) methamphetamine;
- 6 (3) phenmetrazine; and
- 7 (4) methylphenidate;
- 8 (5) lisdexamfetamine, its salts, isomers, and salts of its  
9 isomers.”

10 **Section 8.** Item (B) of Appendix C of Chapter 67 of Title 9 of the Guam  
11 Code Annotated is hereby *amended* to read as follows:

12 “(B) A material, compound, mixture, or preparation containing any quantity  
13 of the following substances having a depressant effect on the central nervous  
14 system:

15 (1) a compound, mixture, or preparation containing any of the  
16 following drugs or their salts and one or more other active medicinal  
17 ingredients not included in any schedule:

- 18 (A) amobarbital;
- 19 (B) secobarbital; and
- 20 (C) pentobarbital;

21 (2) any of the following drugs, or their salts, in suppository dosage  
22 form, approved by the federal Food and Drug Administration for  
23 marketing only as a suppository:

- 24 (A) amobarbital;
- 25 (B) secobarbital, and
- 26 (C) pentobarbital;

1 (3) a substance containing any quantity of a derivative of barbituric  
2 acid or any salt of a derivative of barbituric acid;

3 (A) embutramide

4 (B) any drug product containing gamma hydroxybutyric acid,  
5 including its salts, isomers, and salts of isomers, for which an  
6 application is approved under Section 505 of the Federal Food,  
7 Drug, and Cosmetic Act;

8 (C) ketamine, its salts, isomers, and salts of isomers [some  
9 other names for ketamine: (+)-2-(2-chlorophenyl)-2-  
10 (methylamino)-cyclohexanone].”

11 **Section 9.** Item (D) of Appendix C of Chapter 67 of Title 9 of the Guam  
12 Code Annotated is hereby *amended* to read as follows:

13 “(D) A material compound, mixture, or preparation containing any of the  
14 following narcotic drugs, or their salts calculated as the free anhydrous base  
15 or alkaloid, in limited quantities as set forth below:

16 (1) not more than 1.8 grams of codeine per 100 milliliters or not more  
17 than 90 milligrams per dosage unit, with an equal or greater quantity  
18 of an isoquinoline alkaloid of opium;

19 (2) not more than 1.8 grams of codeine per 100 milliliters or not more  
20 than 90 milligrams per dosage unit, with one or more active,  
21 nonnarcotic ingredients in recognized therapeutic amounts;

22 (3) not more than 300 milligrams of dihydrocodeinone (hydrocodone)  
23 per 100 milliliters or not more than 15 milligrams per dosage unit,  
24 with a fourfold or greater quantity of an isoquinoline alkaloid of  
25 opium;

26 (4) not more than 300 milligrams of dihydrocodeinone (hydrocodone)  
27 per 100 milliliters or not more than 15 milligrams per dosage unit,

1 with one or more active-nonnarcotic ingredients in recognized  
2 therapeutic amounts;

3 (5) not more than 1.8 grams of dihydrocodeine per 100 milliliters or  
4 not more than 90 milligrams per dosage unit, with one or more active,  
5 nonnarcotic ingredients in recognized therapeutic amounts;

6 (6) not more than 300 milligrams of ethylmorphine per 100 milliliters  
7 or not more than 15 milligrams per dosage unit, with one or more  
8 active, nonnarcotic ingredients in recognized therapeutic amounts;(7)

9 not more than 500 milligrams of opium per 100 milliliters or per 100  
10 grams, or not more than 25 milligrams per dosage unit, with one or  
11 more active, nonnarcotic ingredients in recognized therapeutic  
12 amounts; ~~and~~

13 (8) not more than 50 milligrams of morphine per 100 milliliters or per  
14 100 grams with one or more active, nonnarcotic ingredients in  
15 recognized therapeutic amounts; and

16 (9) A material, compound, mixture, or preparation containing any of  
17 the following narcotic drug and its salts: buprenorphine.”

18 **Section 10.** Item (E) of Appendix C of Chapter 67 of Title 9 of the Guam  
19 Code Annotated is hereby *amended* to read as follows:

20 “(E) Anabolic Steroids. (1) Any drug or hormonal substance chemically and  
21 pharmacologically related to testosterone (other than estrogens, progestins,  
22 corticosteroids, and dehydroepiandrosterone), and includes:

23 (1) 3[beta], 17-dihydroxy-5a-androstane;

24 (2) 3[alpha], 17[beta]-dihydroxy-5a-androstane;

25 (3) 5[alpha]-androstane-3,17-dione;

26 (4) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-  
27 androst-1-ene);

- 1 (5) 1-androstenediol (3[alpha],17[beta]-dihydroxy-5[alpha]-  
2 androst-1-ene);
- 3 (6) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene;  
4 (7) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-  
5 ene);
- 6 (8) 1-androstenedione ([5[alpha]]-androst-1-en-3,17-dione;  
7 (9) 4-androstenedione (androst-4-en-3,17-dione);  
8 (10) 5-androstenedione (androst-5-en-3,17-dione);  
9 (11) bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-  
10 hydroxyandrost-4-en-3one);
- 11 (12) Boldenone (17[beta]-hydroxyandrost-1,4,-diene-3-one);  
12 (13) boldione (androsta-1,4-diene-3,17-dione;  
13 (15) calusterone (7[beta],17[alpha]-dimethyl-17[beta]-  
14 hydroxyandrost-4-en-3-one);
- 15 (16) Chlorotestosterone (4-chlortestosterone),  
16 (17) Clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one);  
17 (18) Dehydrochlormethyltestosterone (4-chloro-17[beta]-  
18 hydroxy- 17[alpha]methyl-androst-1,4-dien-3-one);  
19 (19) [Delta] 1-dihydrotestosterone (a.k.a. '1-testosterone')  
20 (17[beta]- hydroxyl-5[alpha]-androst-1 en-3-one);  
21 (20) Dihydrotestosterone (4-dihydrotestosterone);  
22 (21) 4-dihydrotestosterone (17[beta]-hydroxy-androstan-3-one);  
23 (22) Drostanolone (17[beta]-hydroxy-2[alpha]-methyl-5[alpha]-  
24 androstan-3-one);
- 25 (23) Ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-  
26 ene);

1                   (24) Fluoxymesterone (formebolone) (9-fluoro-17[alpha]-  
2                   methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one);  
3                   (25) Formebolone (2-formyl-17[alpha]-methyl-  
4                   11[beta],17[beta]-dihydroxyandrost-1,4-dien-3-one);  
5                   (26) furazabol (17[alpha]-methyl-17-17[beta]-  
6                   hydroxyandrostando[2,3-c]- furazan);  
7                   (27) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one;  
8                   (28) 4-hydroxytestosterone (4,17[beta]-dihydroxy-androst-4-en-  
9                   3-one);  
10                  (29) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxy-estr-  
11                  4-en-3-one);  
12                  (30) desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-  
13                  androst-2-en-17[beta]-ol) (a.k.a., madol);  
14                  (31) Mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5-  
15                  androstan-3-one);  
16                  (32) Mesterolone (1[alpha]methyl-17[beta]-hydroxy-[5[alpha]]-  
17                  androstan-3-one);  
18                  (33) Methandienone (17[alpha]-methyl-17[beta]-  
19                  hydroxyandrost-1,4-dien-3-one);  
20                  (34) mathandriol (17[alpha]-methyl-3[beta],17[beta]-  
21                  dihydroxyandrost-5-ene);  
22                  (35) Methandranone;  
23                  (36) Methandriol;  
24                  (37) Methandrostenolone;  
25                  (38) Methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-  
26                  androst-1-en-3-one);

1 (39) 17[alpha]-methyl-3[beta], 17[beta]-dihydroxy-5a-  
2 androstane;  
3 (40) 17[alpha]-methyl-3[beta],17[beta],17[beta]-  
4 dihydroxyandrost-4-ene;  
5 (41) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-methyl-  
6 4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);  
7 (42) methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-  
8 4,9(10)-dien-3-one);  
9 (43) methyltrienolone (17[alpha]-methyl-17[beta]-  
10 hydroxyestra-4,9- 11-trien-3-one);  
11 (44) Methyltestosterone (17[alpha]-methyl17[beta]-  
12 hydroxyandrost-4-en-3-one);  
13 (45) Mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-  
14 hydroestr-4-en-3-one);  
15 (46) 17[alpha]-methyl-[Delta]1-dihydrotestosterone (17b[beta]-  
16 hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one) (a.k.a.  
17 '17- [alpha]-methyl-1-testosterone');  
18 (48) Nandrolone (17[beta]-hydroxyestr-4-en-3-one);  
19 (49) 19-nor-4-androstenediol (3[beta], 17[beta]-dihydroxyestr-  
20 4-ene);  
21 (50) 19-nor-4-androstenediol (3[alpha], 17[beta]-dihydroxyestr-  
22 4-ene);  
23 (51) 19-nor-4-androstenediol (3[beta], 17[beta]-dihydroxyestr-  
24 5-ene);  
25 (52) 19-nor-4-androstenediol (3[alpha], 17[beta]-dihydroxyestr-  
26 5-ene);

- 1 (53) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-  
2 3,17-dione);  
3 (54) 19-nor-4-androstenedione (estr-4-en-3,17dione);  
4 (55) 19-nor-5-androstenedione (estr-4-en-3,17dione);  
5 (56) norbolethone (13[beta], 17[alpha]-diethyl-17[beta]-  
6 hydroxygon- 4-en-3-one);  
7 (57) norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one);  
8 (58) Norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-  
9 en-3-one);  
10 (59) normethandrolone (17[alpha]-methyl-17[beta]-  
11 hydroxyestr-4-en-3-one);  
12 (60) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-  
13 [5[alpha]]-androstan-3-one);  
14 (61) Oxymesterone (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-  
15 [5[alpha]]-androstan-3-one);  
16 (62) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-  
17 17[beta]-hydroxy-[5[alpha]]-androstan-3-one);  
18 (63) Stanolone;  
19 (64) Stanozolol (17[alpha]-methyl-17[beta]-hydroxy-[5[alpha]]-  
20 androst-2-eno[3,2-c]-pyrazole);  
21 (65) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-  
22 dien-17-oic acidlactone);  
23 (66) Testosterone (17[beta]-hydroxyandrost-4-en-3-one);  
24 (67) tetrahydrogestrinone (13[beta], 17[alpha]-diethyl-17[beta]-  
25 hydroxygon-4,9,11-trien-3-one);  
26 (68) Trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one);

27 and

1 (2) Any salt, ester, or isomer of a drug or substance described  
2 or listed in (1), if that salt, ester, or isomer promotes muscle growth.  
3 Except such term does not include an anabolic steroid which is  
4 expressly intended for administration through implants to cattle or  
5 other nonhuman species and which has been approved by the  
6 Secretary of Health and Human Services for such administration. If  
7 any person prescribes, dispenses, or distributes such steroid for human  
8 use, such person shall be considered to have prescribed, dispensed, or  
9 distributed an anabolic steroid within the meaning of this paragraph.

10 DPHSS may exempt by rule a compound, mixture, or  
11 preparation containing a stimulant or depressant substance listed in  
12 subsections A and B from the application of all or part of this Act, if  
13 the compound, mixture, or preparation contains one or more active  
14 medicinal ingredients not having a stimulant or depressant effect on  
15 the central nervous system and the admixtures are in combinations,  
16 quantity, proportion, or concentration that vitiate the potential for  
17 abuse of the substances having a stimulant or depressant effect on the  
18 central nervous system.”

19 **Section 11.** A new Item (F) is hereby *added* to Appendix C of Chapter 67 of  
20 Title 9 of the Guam Code Annotated, to read as follows:

21 “(F) Dronabinol (synthetic) in sesame oil and encapsulated is a soft gelatine  
22 capsule in a U.S. Food and Drug Administration approved product [Some  
23 other names for dronabinol: (6aR-trans)-6a, 7, 8, 10a-tetrahydro-6,6,9-  
24 trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol] or (-)-delta-9-(trans)-  
25 tetrahydrocannabinol].”

26 **Section 12.** Item (B) of Appendix D of Chapter 67 of Title 9 of the Guam  
27 Code Annotated is hereby *amended* to read as follows:



1 “(B) A material, compound, mixture, or preparation containing any quantity  
2 of the following substances having a depressant effect on the central nervous  
3 system, including any salts, isomers, and salts of isomers of them that are  
4 theoretically possible within the specific chemical designation:

- 5 (1) alprazol.am;
- 6 (2) barbital;
- 7 (3) bromazepam;
- 8 (4) camazepam;
- 9 (5) chloral betaine;
- 10 (6) chloral hydrate;
- 11 (7) chlordiazepoxide;
- 12 (8) clobazam;
- 13 (9) clonazepam;
- 14 (10) clorazepate;
- 15 (11) clotiazepam;
- 16 (12) cloxazolam;
- 17 (13) delorazepam;
- 18 (14) diazepam;
- 19 (15) dichloraphenazone;
- 20 ~~(15)~~ (16) estazolam;
- 21 ~~(16)~~ (17) ethchlorvynol;
- 22 ~~(17)~~ (18) ethinamate;
- 23 ~~(18)~~ (19) ethylloflazepate;
- 24 ~~(19)~~ (20) fludiazepam;
- 25 ~~(20)~~ (21) flunitrazepam;
- 26 ~~(21)~~ (22) flurazepam;
- 27 (23) fospropofol;

1                    ~~(22)~~ (24) halazepam;  
2                    ~~(23)~~ (25) haloxazolam;  
3                    ~~(24)~~ (26) ketazolam;  
4                    ~~(25)~~ (27) loprazolam;  
5                    ~~(26)~~ (28) lorazepam;  
6                    ~~(27)~~ (29) lormetazepam;  
7                    ~~(28)~~ (30) mebutamate;  
8                    ~~(29)~~ (31) medazepam;  
9                    ~~(30)~~ (32) meprobamate;  
10                   ~~(31)~~ (33) methohexital;  
11                   ~~(32)~~ (34) methylphenobarbital (mephobarbital);  
12                   ~~(33)~~ (35) midazolam;  
13                   ~~(34)~~ (36) nimetazepam;  
14                   ~~(35)~~ (37) nitrazepam;  
15                   ~~(36)~~ (38) nordiazepam;  
16                   ~~(37)~~ (39) oxazepam;  
17                   ~~(38)~~ (40) oxazolam;  
18                   ~~(39)~~ (41) paraldehyde;  
19                   ~~(40)~~ (42) petrichloral;  
20                   ~~(41)~~ (43) phenobarbital;  
21                   ~~(42)~~ (44) pinazepam;  
22                   ~~(43)~~ (45) prazepam;  
23                   ~~(44)~~ (46) quazepam;  
24                   ~~(45)~~ (47) temazepam;  
25                   ~~(46)~~ (48) tetrazepam;  
26                   ~~(47)~~ (49) triazolam; and  
27                   (50) zaleplon

1                   ~~(48)~~ (51) zolpidem

2                   (52) zopiclone”

3           **Section 13.** Item (D) of Appendix D of Chapter 67 of Title 9 of the Guam  
4 Code Annotated is hereby *amended* to read as follows:

5           “(D) A material, compound, mixture, or preparation containing any quantity  
6 of the following substances having a stimulant effect on the central nervous  
7 system, including their salts, isomers, and salts of isomers:

8                   (1) cathine;

9                   (2) diethylpropion;

10                  (3) fencamfamin;

11                  (4) fenproporex;

12                  (5) mazindol;

13                  (6) mefenorex;

14                  (7) modafinil;

15                  ~~(7)~~ (8) pemoline (including organometallic complexes and  
16 chelates thereof);

17                  ~~(8)~~ (9) phentermine;

18                  ~~(9)~~ (10) pipradrol; ~~and~~

19                         (11) sibutramine:

20                         ~~(10)~~ (12) SPA ((-)-i-dimethylamino-1,2-diphenylethane);”

21           **Section 14.** Item (D) of Appendix E of Chapter 67 of Title 9 of the Guam  
22 Code Annotated is hereby *amended* to read as follows:

23           “(C) A material, compound, mixture, or preparation containing any quantity  
24 of the following substances having a stimulant effect on the central nervous  
25 system, including their salts, isomers and salts of isomers:

26                         (1) lacosamide [(R)-2-acetoamido- N –benzyl-3-methoxy-  
27                         propionamide];

1                                   (2) pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid];  
2                                   ~~(1)~~ (3) pyrovalerone;”

3           **Section 15.** A new §3106.1 is hereby *added* to Article 1 of Chapter 3 of Title  
4 10 of the Guam Code Annotated, to read as follows:

5           **“§3106.1 Guam Uniform Controlled Substance Act Review.**

6           The Director shall, in accordance with the Administrative Adjudication Law,  
7 conduct a biannual review of the U.S. Drug Enforcement Administration Schedule  
8 Listing to determine whether the Guam Uniform Controlled Substance Act shall be  
9 revised in accordance.”

10           **Section 16. Effective Date.** This act shall take effect immediately upon  
11 enactment.